Clinical reports on cancer

Cholangiocarcinoma

Male in the 80s
Chief Complaint: Jaundice
Past Medical history: No significant diseases

Current medical history:
He visited a nearby hospital complaining of, primarily, jaundice in July 2013. In a bile duct cancer examination, tumors were found in the hepatic portal section and the bile duct, and obstructive jaundice was developed. A PTCD-tube was inserted on July 16, 2013 and followed by a stent on August 23 in an attempt to reduce pressure in the bile duct and mitigate jaundice. He visited our hospital seeking for palliative care in September 9, 2013. He began fucoidan therapy, without any aggressive treatments including chemotherapy (his family members also declined such treatments), taking his age into consideration.

Treatment Outcomes:
His tumor shrank with only fucoidan therapy. CA-19-9 levels were improved to 434.4 from 1170, and the levels of ALP were improved to 509 from 1179, and the levels of γ-GTP also were improved to 13 from 230. The jaundice disappeared and he had no further pain.

※Data taken over the period of treatment

《CT images of the abdomen》

Fucoidan mix intake per day: Approximately 4.0g

clinical_index07_03
September 2013
clinical_index07_04
June 2014

 

【Tumor markers】

September 2013 June 2014
CA19-9(≦ 37.0) 1170.0 434.4 (U/ml)

 

【Biochemistry tests】

September 2013 June 2014
ALP(115 ~ 359) 1179 509 (U/l)
γ-GTP (< 70) 230 13 (U/l)

Bile duct cancer, liver metastasis and bone metastasis

Male in his 40s
Chief Complaint: No significant symptoms
Past Medical History: Not significant

Current Medical History:
In March 2011, he was diagnosed with stage Ⅳ bile duct cancer, and the tumor had spread to the liver and bones. In April the same year, he began fucoidan therapy in combination with chemotherapy.

Treatment Outcomes:
He began fucoidan therapy in April 2011. By July the same year, the size of tumor was reduced to 2.0cm × 2.0cm from 2.9cm × 2.3cm. There were no side effects from chemotherapy, and the QOL was also improved.

※Data taken over the period of treatment

《CT images of abdomen》

Fucoidan mix intake per day: Approximately 5.0g

clinical_index07_01
Tumor size:2.9cm×2.3cm
March 2011
clinical_index07_02
Tumor size:2.0cm×2.0cm
July 2011


Fucoidan mix・・・It is composed of mozuku extracted fucoidan, mekabu extracted fucoidan and agaricus mycelium.

Today, active research is conducted on fucoidan and various bioactive functions of fucoidan, such as “anti-cancer action,” “cholesterol-lowering action,” “blood-pressure lowering action” and “anti-virus action,” have been revealed.

Back to Top